3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.

A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3beta was developed from a low molecular weight, highly ligand efficient screening hit 1. Hit-to-lead optimization led to a number of highly potent inhibitors, while maintaining the high ligand efficiency of the screening hit.

[1]  P. Lam,et al.  Stereoselective synthesis of an analog of podophyllotoxin by an intramolecular Diels-Alder reaction , 1985 .

[2]  P. Shaw,et al.  Expression analysis of glycogen synthase kinase-3 in human tissues. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[3]  Tudor I. Oprea,et al.  The Design of Leadlike Combinatorial Libraries. , 1999, Angewandte Chemie.

[4]  Jesús Avila,et al.  The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease , 2008, FEBS letters.

[5]  Patrizia Crivori,et al.  Structure-Based Approaches to Improve Selectivity: CDK2-GSK3beta Binding Site Analysis , 2005, J. Chem. Inf. Model..

[6]  A. Clerk,et al.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis , 2008, British journal of pharmacology.

[7]  Jongsoon Lee,et al.  The role of GSK3 in glucose homeostasis and the development of insulin resistance. , 2007, Diabetes research and clinical practice.

[8]  Simon Lovestone,et al.  The GSK3 hypothesis of Alzheimer's disease , 2008, Journal of neurochemistry.

[9]  J. Woodgett,et al.  Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation , 2000, Nature.

[10]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[11]  M. Medina,et al.  Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. , 2008, Current opinion in drug discovery & development.

[12]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[13]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[14]  K. Wilson,et al.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase , 1998, Protein science : a publication of the Protein Society.

[15]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[16]  D. Chuang,et al.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder , 2007, Neuroscience & Biobehavioral Reviews.

[17]  Kirk W. Johnson,et al.  Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. , 2004, Current pharmaceutical design.

[18]  A. Ray,et al.  Glycogen synthase kinase 3: more than a namesake , 2009, British journal of pharmacology.

[19]  M. Roh,et al.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.

[20]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[21]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[22]  D. Gingrich,et al.  Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease , 2009 .

[23]  Michel Goedert,et al.  GSK3 inhibitors: development and therapeutic potential , 2004, Nature Reviews Drug Discovery.

[24]  A Aitken,et al.  Separation and characterisation of glycogen synthase kinase 3, glycogen synthase kinase 4 and glycogen synthase kinase 5 from rabbit skeletal muscle. , 1982, European journal of biochemistry.